Back to News​
Press Release

Alamar Biosciences joins forces with SciLifeLab to advance understanding of human disease

Back to Publications​
  • May 28, 2025

Fremont, CA – Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease is proud to announce a strategic collaboration with SciLifeLab to advance translational proteomics and accelerate biomarker discovery.

The partnership brings together Alamar’s NULISA™ technology and ARGO™ HT system—offering ultra-sensitive, multiplexed protein analysis from biofluids—with SciLifeLab’s Proteomics Capabilities and its extensive data resources, including the Human Protein Atlas, a research program that maps the human proteome. Together, the organizations aim to deepen understanding of disease biology and drive development of early diagnostic tools.

“We are thrilled to partner with SciLifeLab in this important work,” Dr. Yuling Luo, Chairman, Founder & CEO of Alamar Biosciences stated. “Our combined technologies will provide comprehensive data on protein expression and localization, which will be instrumental in validating signatures discovered using the NULISA platform.”

“SciLifeLab’s expertise in affinity proteomics, combined with our national infrastructure and partnership with National Genomics Infrastructure, makes this a natural environment for a cutting-edge technology like the ARGO HT System,” said Professor Jochen Schwenk, SciLifeLab Group Leader and Platform Scientific Director of Proteomics. “We look forward to enabling new levels of sensitivity, scalability, and integration in biomarker discovery.”

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com

About SciLifeLab

SciLifeLab is Sweden’s national center for molecular biosciences, jointly operated by Karolinska Institutet, KTH Royal Institute of Technology,flm University, and Uppsala University. It provides unique research infrastructure and data resources, and fosters collaboration between academia, healthcare, and industry. With more than 40 national infrastructure units and around 1,500 researchers, SciLifeLab is a leading hub for life science innovation and translational research. For more information, visit www.scilifelab.se.

Linkedin

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Linkedin

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition.  He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.